An observational study in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Active, not recruiting at 31 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Intergroupe Francophone du Myelome · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome — 1 open to participants now, 4 under way, 2 of them phase 3. Multiple Myeloma · Intergroupe Francophone du Myelome.
Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, this one is the only one that started in 2023, is one of 3 observational ones, and was the 9th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →1 of the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome is open now, in 2 countries. Recruiting first, the newest first:
Intergroupe Francophone du Myelome · Sites in Belgium, France
Ages 18–69
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 205 across the 7 interventional studies, 180 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Intergroupe Francophone du Myelome is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
1 of the studies in Multiple Myeloma by Intergroupe Francophone du Myelome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06062537Intergroupe Francophone du MyelomeAnalysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria.
This is a multicenter, prospective, observational study.
French adult patient relapsed and refractory multiple myeloma receving teclistamab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
overall response rate (ORR) of teclistamab according to IMWG criteria
ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.
Time frame: 6 months
overall response rate (ORR) of teclistamab according to IMWG criteria
ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.
Time frame: 24 months
Effectiveness of teclistamab
Progression Free Survival 1 and 2 (PFS)
Time frame: 24 months
Effectiveness of teclistamab
Overall survival (OS)
Time frame: 24 months
Effectiveness of teclistamab
Duration of overall response (DOR)
Time frame: 24 months
Effectiveness of teclistamab
Response rate (sCR, CR, VGPR, PR)
Time frame: 24 months
Effectiveness of teclistamab
Time to best response
Time frame: 24 months
Effectiveness of teclistamab
Time to next treatment (TTNT)
Time frame: 24 months
Effectiveness of teclistamab
Time to discontinuation (TTD)
Time frame: 24 months
Adverse events of interest
ICANS, CSR and infections
Time frame: 24 months
Conditions of use
Patients' profiles (demographics characteristics and medical history) \- Injection facilities and schedules during step-up dosing phase
Time frame: 1 month
Conditions of use
Patients' profiles (demographics characteristics and medical history) \- Injection facilities and schedules during follow up phase
Time frame: 24 months
Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.
Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 33. This study's planned 39 months is below that.
Counting every sponsor, half of 239 studies reached it within 61 months; a quarter within 30 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intergroupe Francophone du Myelome